Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Argent Biopharma (RGT) Share Price & Analysis

7 Followers

RGT Stock Chart & Stats

A$0.02A$0.00(10.53%)
At close: 4:00 PM GMT+11
AU$0.02AU$0.03AU$0.04Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
AUD 0.02 - AUD 0.02
52-Week Range
AUD 0.02 - AUD 0.11
Previous Close
AUD 0.02
Volume
N/A
Average Volume (3M)
70.96K
Market Cap
AUD 2.24M
Enterprise Value
AUD 12.72M
Total Cash (Recent Filing)
AUD 141.46K
Total Debt (Recent Filing)
AUD 9.59M
Price to Earnings (P/E)
―
Beta
-1.32
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Operating Cash Flow

The reduction in operating cash outflow shows some improvement in near-term cash discipline compared with the prior year. Although Argent Biopharma remains cash-burning and cannot yet self-fund operations, this change could provide additional time to execute its business plans if sustained.

Historical Positive Equity

Positive equity in 2021 and 2022 demonstrates that the company has previously maintained a stronger capital position. This history does not offset current balance-sheet stress, but it indicates that financial recovery is not entirely without precedent if operating performance improves.

Earlier Gross Profit Generation

The company’s ability to generate positive gross profit through 2025 shows that its products and commercial activities have previously produced revenue above direct costs. The later reversal is serious, but the historical result provides evidence of prior underlying product-level viability.

Bears Say

Sharp Revenue Contraction

A steep revenue decline following several years of contraction signals weakening commercial traction and reduces the scale available to support research, regulatory, and operating expenses. Unless reversed, the shrinking revenue base will continue to impair earnings potential and strategic flexibility.

Severe Profitability Deterioration

Negative gross profit means current revenue is not covering direct costs, while very large operating and net losses indicate that the broader cost base is also unsustainable at present sales levels. This weakens internal funding capacity and makes a durable return to profitability more difficult.

Stressed Balance Sheet

Negative equity and debt materially exceeding the asset base indicate a thin financial cushion for creditors and shareholders. This structure limits capital-allocation flexibility, increases refinancing pressure, and leaves the company more vulnerable if losses and cash requirements persist.

Argent Biopharma News

RGT FAQ

What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest share price was AU$0.02 and its highest was AU$0.11 in the past 12 months.
What is Argent Biopharma’s market cap?
Argent Biopharma’s market cap is AU$2.24M.
When is Argent Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Argent Biopharma’s earnings last quarter?
Argent Biopharma released its earnings results on Feb 27, 2026. The company reported -AU$0.038 earnings per share for the quarter.
Is Argent Biopharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Argent Biopharma pay dividends?
Argent Biopharma does not currently pay dividends.
What is Argent Biopharma’s EPS estimate?
Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argent Biopharma have?
Argent Biopharma has 117,859,580 shares outstanding.
What happened to Argent Biopharma’s price movement after its last earnings report?
Argent Biopharma reported an EPS of -AU$0.038 in its last earnings report. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Argent Biopharma?
Currently, no hedge funds are holding shares in AU:RGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology